Download Free Medical United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 - Booklet 3 PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 is presented in six separate booklets. The report gives detailed information and analysis to support the international community in implementing operational recommendations present in the outcome document of the special session of the General Assembly on the world drug problem, held in 2016 Booklet 3 of the United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 is about drug supply. The report presents the latest estimates and trends regarding the production of and trafficking in opiates, cocaine, amphetamine-type stimulants and cannabis.

Tags : United Nations Office on Drugs and Crime, UNODC, summary, World Drug Report 2020, General Assembly, world drug problem, drug supply

Published on : Jun 30, 2020 | Views : 2400 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

ppt slide no 1 content not found
Slide 2-

Global seizures
Slide 3-

ppt slide no 3 content not found
Slide 4-

Global opium cultivation and production
Slide 5-

Opium and heroin prices in Afghanistan
Slide 6-

Global opium production and opioids seizures
Slide 7-

Opiates seized, 2018
Slide 8-

Regional distribution of opiates seized
Slide 9-

Regional trends in opiates seized
Slide 10-

ppt slide no 10 content not found
Slide 11-

Opiate seizures along main trafficking routes
Slide 12-

Sources of heroin in the United States
Slide 13-

ppt slide no 13 content not found
Slide 14-

Coca cultivation and cocaine manufacture
Slide 15-

Coca cultivation in Colombia
Slide 16-

Coca cultivation/manufacture in Colombia
Slide 17-

Coca cultivation in the Plurinational State of Bolivia
Slide 18-

Distribution of cocaine seizures, 2018
Slide 19-

Trends in global cocaine seizures, 1998-2018
Slide 20-

ppt slide no 20 content not found
Slide 21-

Origin of cocaine in Australia
Slide 22-

ppt slide no 22 content not found
Slide 23-

Global ATS seizures, 1998 ̶ 2018
Slide 24-

Distribution of ATS seizures by region
Slide 25-

Distribution of ATS seizures by substance and region
Slide 26-

Methamphetamine, labs and precursors seized
Slide 27-

Dismantled methamphetamine labs in the United States and China
Slide 28-

Methamphetamine seized
Slide 29-

Methamphetamine seized
Slide 30-

Methamphetamine seized
Slide 31-

Methamphetamine seized
Slide 32-

Amphetamine seized
Slide 33-

Amphetamine seized
Slide 34-

Captagon seized
Slide 35-

“Ecstasy” precursors
Slide 36-

“Ecstasy” seizures
Slide 37-

“Ecstasy” seizures
Slide 38-

“Ecstasy” seizures, 2018
Slide 39-

Significant individual seizures of “ecstasy”
Slide 40-

Major source countries of “ecstasy”
Slide 41-

ppt slide no 41 content not found
Slide 42-

Cannabis cultivation trends
Slide 43-

Countries characterized by significant cannabis cultivation in various regions
Slide 44-

Cannabis cultivation trends
Slide 45-

Cannabis seizure trends
Slide 46-

Cannabis herb trafficking
Slide 47-

Cannabis herb trafficking
Slide 48-

Cannabis resin trafficking
Slide 49-

Click to edit Master title style
Slide 50-

ppt slide no 50 content not found
Slide 51-

ppt slide no 51 content not found
Slide 52-

ppt slide no 52 content not found
Slide 53-

Click to edit Master title style
Slide 54-

ppt slide no 54 content not found
Slide 55-

ppt slide no 55 content not found
Slide 56-

ppt slide no 56 content not found
Slide 57-

ppt slide no 57 content not found
Slide 58-

Click to edit Master title style
Slide 59-

ppt slide no 59 content not found
Slide 60-

ppt slide no 60 content not found
Slide 61-

ppt slide no 61 content not found
Slide 62-

Click to edit Master title style
Slide 63-

ppt slide no 63 content not found
Slide 64-

ppt slide no 64 content not found
Slide 65-

ppt slide no 65 content not found
Slide 66-

ppt slide no 66 content not found
Slide 67-

Click to edit Master title style
Slide 68-

ppt slide no 68 content not found
Slide 69-

ppt slide no 69 content not found
Slide 70-

ppt slide no 70 content not found
Slide 71-

Click to edit Master title style
Slide 72-

ppt slide no 72 content not found
Slide 73-

ppt slide no 73 content not found
Slide 74-

ppt slide no 74 content not found
Slide 75-

ppt slide no 75 content not found
Slide 76-

Click to edit Master title style
Slide 77-

ppt slide no 77 content not found
Slide 78-

ppt slide no 78 content not found
Slide 79-

ppt slide no 79 content not found
Slide 80-

Click to edit Master title style
Slide 81-

ppt slide no 81 content not found
Slide 82-

ppt slide no 82 content not found
Slide 83-

ppt slide no 83 content not found
Slide 84-

ppt slide no 84 content not found
Slide 85-

Click to edit Master title style
Slide 86-

ppt slide no 86 content not found
Slide 87-

ppt slide no 87 content not found
Slide 88-

ppt slide no 88 content not found
Slide 89-

Click to edit Master title style
Slide 90-

ppt slide no 90 content not found
Slide 91-

ppt slide no 91 content not found
Slide 92-

ppt slide no 92 content not found
Slide 93-

Click to edit Master title style
Slide 94-

ppt slide no 94 content not found
Slide 95-

ppt slide no 95 content not found
Slide 96-

Click to edit Master title style
Slide 97-

Click to edit Master title style
Slide 98-

Click to edit Master title style

User Presentation
Related Presentations

About : An experienced pharma professional managing sales, marketing and brand management of top global pharma products Presently leading a team of experts in the development and execution of pharma eCommerce strategies that support GSK products to HCP customers.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : United States of America
Website :

High-Performance Pharma Brand Plans - The 5 Pitfalls to avoid

COVID-19 immunology research

Evaluate Vantage Report on impact of COVID-19 Biopharma and Medtech

Rare Diseases and the Orphan Drug Act in the US

The financialisation of Big Pharma

Clinical Pharmacology Considerations During Phase 2 and Phase 3 of Drug Development

Intelligent Systems and Molecular Biology

Neuroleptics Anxiolytics

Pharmacogenetics and Pharmacogenomics

Antibiotics

HEALTH A TO Z